Golden, Colorado-April 6, 2021 — Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Our Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19. [Read more…]
New Lab at UF’s Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research
Noninvasive cellular and acellular therapies will lead to life-extending medicines and treatments, including post-COVID anti-inflammation therapy. A new partnership between the world’s top university for biotech business incubation and Neobiosis, a global expert in regenerative medicine, may fuel a healthcare revolution.
Alachua, FLA., January 19, 2021 – The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA “Post-COVID Syndrome”) will be one of many focuses of a new Research & Development laboratory recently launched at the University of Florida Sid Martin Innovate Biotechnology Institute, the world-recognized leader in biotechnology incubation(1). Neobiosis, which produces regenerative tissues, cells and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate the laboratory at the biotech center, located in Alachua, Fla. [Read more…]
Stem Cell Stocks: A Complete List from “A” to “Z”
Biotech investing has become an increasingly popular in recent years. Whether you’re new to stem cell stocks or you’ve been around the block, now could be a good time to place your bets.
The stock market had its largest point drop in recent history on March 9, 2020. On March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered since then, market prices remain attractive across many sectors.
Furthermore, stem cell companies have received substantial support for their use as living therapeutics against COVID-19 induced respiratory complications, such as ARDS. Given these conditions, an intriguing niches within biotech investing is stem cell stocks. [Read more…]
Helixmith Announces the Development of Botanical Therapeutic Product for Respiratory Diseases, TADIOS
Encouraging animal model efficacy data has been published in Journal of Ethnopharmacology
Clinical trial of 100 patients diagnosed with COVID-19 to begin soon in India
TADIOS found to have anti-inflammatory, anti-oxidative activities and therapeutic effects in acute lung injury animal model
January 14, 2021 – Helixmith Co., Ltd. has announced that TADIOS (HX110), a respiratory treatment developed by the company, showed lung damage-suppressing capability in an acute lung injury mouse model. The results have been published in the Journal of Ethnopharmacology. Helixmith plans to conduct a clinical trial in India to assess if TADIOS can be used as a COVID-19 treatment. Helixmith has signed an agreement with a contract research organization (CRO) that has extensive experience and capacities in the conduct of clinical trials in India. The clinical trial will be conducted in accordance with the regulations of the Ministry of AYUSH, India’s traditional medicine regulatory body, and will begin in February with 100 subjects. [Read more…]
Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19
With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.
Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).
In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]
